Overview
- Kalshi launched the pilot with AppliedXL on Thursday, July 16, 2026, listing more than a dozen contracts tied to Phase 3 trial primary endpoints and full FDA approval decisions after enrollment closed.
- Each contract will be settled against a named public record such as the registered primary endpoint on ClinicalTrials.gov, an FDA approval letter, or an advisory committee voting record with settlement criteria set before trading opens.
- Kalshi and AppliedXL require employment verification and bar trading by people with material nonpublic information and by trial participants, and they say they will monitor activity for insider trading.
- Researchers and bioethicists warn the markets could still enable insider trading or prompt investigators or patients to change behavior in ways that might distort trial results, especially for endpoints that require subjective judgment.
- The pilot drew measurable early volume, roughly $100,000 to $130,000, and has already attracted attention from lawmakers and regulators who may seek tighter rules or oversight of bets tied to manipulable outcomes.